Search earnings tickers

ALNY

2024Q3BMO

Alnylam Pharmaceuticals Inc primary · HEALTHCARE · BIOTECHNOLOGY

Report 2024-10-31 · Fiscal end 2024-09-30 · Features as of 2024-10-30

← Earnings history

Street

Consensus EPS-0.39

Consensus rev—

EPS high—

EPS low—

Dispersion—

Analysts—

EPS rev net 7d—

EPS rev net 30d—

Consensus Δ 7d—

Consensus Δ 30d—

Options

Implied move2.4%

IV front—

P/C full—

P/C front—

Features as of2024-10-30

Run-up

Close—

Ret 5d-4.5%

Ret 10d-6.3%

Ret 20d+3.7%

Ret 30d+3.1%

Print

Actual EPS

-0.50Miss

Estimated EPS-0.39

Actual revenue

500.9M

Surprise %-28.2%

Beat / missMiss

Beat streak 40

Beat streak 80

Reaction

1-day stock reaction-3.2%

Implied vs actual

Implied 2.4%Actual 2.2%

Gap reaction-2.2%

Day result-5.3%

Next-day upNo

Realized / IV0.91×

Post tape

Post 5d+2.1%

Post 10d-3.3%

Post volume1.6M

Vol ×10d1.83×

Vol ×20d2.00×

Post range4.5%